erlotinib hydrochloride has been researched along with imatinib mesylate in 61 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (imatinib mesylate) | Trials (imatinib mesylate) | Recent Studies (post-2010) (imatinib mesylate) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 11,477 | 960 | 5,773 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | imatinib mesylate (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 0.31 | |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | 0.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 28 (45.90) | 29.6817 |
| 2010's | 32 (52.46) | 24.3611 |
| 2020's | 1 (1.64) | 2.80 |
| Authors | Studies |
|---|---|
| Sánchez De Cos Escuín, J | 1 |
| Couzin, J | 1 |
| Kobayashi, K | 1 |
| Nishio, K | 1 |
| Vastag, B | 1 |
| Blum, HE; Geissler, M; Grimm, CF | 1 |
| Kurisu, K; Okamura, T | 1 |
| Christoffersen, T; Dajani, O; Guren, TK; Thoresen, GH; Tveit, KM; Wisløff, F | 1 |
| Sun, Y; Wang, Y | 1 |
| Li, Zi; Lu, S; Yu, YF | 1 |
| Altavilla, G; Rosell, R; Salazar, F; Santarpia, M; Tarón, M | 1 |
| Bonn, S; Bossemeyer, D; Breitenlechner, CB; Engh, RA; Erlbruch, A; Gassel, M; Herrero, S; Lehmann, W | 1 |
| Becker, JC; Domschke, W; Muller-Tidow, C; Pohle, T; Serve, H | 1 |
| Filov, VA; Gershanovich, ML; Imianitov, EN; Stukov, AN | 1 |
| Levitzki, A; Mishani, E | 1 |
| Curtiss, FR | 1 |
| Garber, K | 1 |
| Burris, HA; Cucullu, H; Farley, C; Greco, FA; Hainsworth, JD; Hart, LL; Sosman, JA; Spigel, DR; Sylvester, L; Waterhouse, DM; Yost, K | 1 |
| Giordano, S; Petrelli, A | 1 |
| Chevreau, C; Delord, JP; Deslandres, M; Sibaud, V | 1 |
| Burgin, S; Heidary, N; Naik, H | 1 |
| Fojo, T | 1 |
| Liau, LM; Salgaller, ML | 1 |
| Dorans, K | 1 |
| Gelderblom, H; Guchelaar, HJ; van Erp, NP | 1 |
| Chahbouni, A; den Burger, JC; Sinjewel, A; Vos, RM; Wilhelm, AJ | 1 |
| De Greve, J; Decoster, L; Fontaine, C; Schallier, D; Trullemans, F | 1 |
| Gelderblom, H; Guchelaar, HJ; Pander, J | 1 |
| Geoerger, B; Leblond, P | 1 |
| Amihai, D; Gilad, Y; Gorzalczany, Y; Hammel, I; Merimsky, O; Sagi-Eisenberg, R | 1 |
| Cunningham, D; Yim, KL | 1 |
| Brdar, I; Deng, X; Faessler, R; Mani, NS; Roessler, A; Sales, ZS; Wu, J | 1 |
| Bertucci, F; Chetaille, B; Guiramand, J; Launay, SG; Medina, F; Moureau-Zabotto, L; Nazarian, S; Perrot, D | 1 |
| Daw, HA; Peerzada, MM; Spiro, TP | 1 |
| Amberger-Murphy, V; Clarke, C; Clynes, M; Doolan, P; Farrell, M; Howley, R; Kinsella, P; Madden, SF | 1 |
| Pick, A; Wiese, M | 1 |
| Ho, WL; Wong, H; Yau, T | 1 |
| Andriamanana, I; Duretz, B; Gana, I; Hulin, A | 1 |
| Ashby, CR; Chen, ZS; Kathawala, RJ; Wang, YJ | 1 |
| Ding, JF; Zhong, DF | 1 |
| Beijnen, JH; Huitema, AD; Knapen, LM; Lankheet, NA; Schellens, JH; Steeghs, N | 1 |
| Behera, R; Mensa-Wilmot, K; Thomas, SM | 1 |
| Liu, D; Yang, Y; Zhao, S | 1 |
| Hohenforst-Schmidt, W; Huang, H; Kakolyris, S; Kioumis, I; Lampaki, S; Li, Q; Organtzis, J; Papaiwannou, A; Petridis, D; Pitsiou, G; Porpodis, K; Syrigos, K; Tsiouda, T; Turner, JF; Zarogoulidis, K; Zarogoulidis, P | 1 |
| Cooke, LS; Kurtzman, D; Mahadevan, D; Morales, C; Ong, E; Qi, W; Stejskal, AE; Swart, R; Theiss, N; Zhu, M | 1 |
| Bidart, JM; Broutin, S; Gil, S; Goffinet, F; Jovelet, C; Mir, O; Paci, A; Seck, A; Simasotchi, C | 1 |
| Boulin, M; Chretien, ML; Lang, AS; Mounier, M; Roques, M | 1 |
| Bekerman, E; Einav, S | 1 |
| Huang, Z; Liu, P; Qian, J; Shu, Y; Wu, Y; Zhou, X; Zhu, W | 1 |
| Bower, M; Erbacher, I; Fortunak, J; Gotham, D; Hill, A; Levi, J; Martin, M; Meldrum, J; Powderly, WG; Shoman, H | 1 |
| Broutin, S; Gil, S; Jovelet, C; Mir, O; Paci, A | 1 |
| Heath, JR; Johnson, H; Kravchenko-Balasha, N; Levine, RD; White, FM | 1 |
| Amano, S; Aoyama, M; Hino, N; Inoue, S; Miyoshi, T; Mori, R; Sumitomo, H; Wada, D | 1 |
| Griffith, N; Kolli, S; Li, Q; Liu, Z; Poi, MJ; Wetz, K | 1 |
| Bugyik, E; Dezső, K; Mózes, M; Nagy, P; Paku, S; Rókusz, A; Szücs, A; Veres, D | 1 |
| Bay, JO; Bertucci, F; Blay, JY; Bompas, E; Bonneville-Levard, A; Chauffert, B; Chevreau, C; Cupissol, D; Duffaud, F; Fabbro, M; Feuvret, L; Le Cesne, A; Lebellec, L; Mir, O; Noel, G; Penel, N; Saada-Bouzid, E; Vauleon, E; Vinceneux, A | 1 |
| Alas, V; Boulanger, L; Goertz, HP; Reyes, C; Stokes, M; Xia, Y | 1 |
| Allard, M; Bellesoeur, A; Blanchet, B; Cardoso, E; Rousseau, B | 1 |
| Kim, HS; Kim, JY; Yoon, S | 1 |
| Eskiköy Bayraktepe, D; Yazan, Z; Yıldız, C | 1 |
26 review(s) available for erlotinib hydrochloride and imatinib mesylate
| Article | Year |
|---|---|
[New therapeutic targets and strategies in lung cancer].
Topics: Alkyl and Aryl Transferases; Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Benzodiazepines; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Endothelial Growth Factors; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Gefitinib; Humans; Imatinib Mesylate; Imidazoles; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Lymphokines; Metalloendopeptidases; Multicenter Studies as Topic; Piperazines; Polyisoprenyl Phosphates; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Quinolones; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Sesquiterpenes; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
[Lung cancer: molecular targeting therapy].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gene Targeting; Genetic Therapy; Humans; Imatinib Mesylate; Indoles; Lung Neoplasms; Piperazines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Trastuzumab | 2004 |
[Resistance to target-based therapy and its circumvention].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Cetuximab; Drug Delivery Systems; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Quinazolines; Rituximab; Trastuzumab | 2004 |
[Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, abl; Humans; Imatinib Mesylate; Neoplasms; Patient Selection; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Trastuzumab; Vascular Endothelial Growth Factor A | 2005 |
[Molecular targeted therapy for malignant brain tumors].
Topics: Antineoplastic Agents; Benzamides; Brain Neoplasms; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioma; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Piperidines; Protein Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2005 |
[Antineoplastic agents targeting tyrosine kinases].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gastrointestinal Stromal Tumors; Gefitinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Trastuzumab | 2005 |
From the bench to the bed: individualizing treatment in non-small-cell lung cancer.
Topics: 14-3-3 Proteins; Adenocarcinoma; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; DNA Damage; DNA Repair; Epistasis, Genetic; ErbB Receptors; Erlotinib Hydrochloride; Genes, BRCA1; Genes, cdc; Genes, erbB-1; Genes, ras; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Lung Neoplasms; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Piperazines; Polymorphism, Genetic; Pyrimidines; Quinazolines | 2006 |
Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Stomach Neoplasms; Trastuzumab | 2006 |
[Problems in the current target therapy of malignancies].
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Azathioprine; Benzamides; Bevacizumab; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Phthalazines; Piperazines; Pyridines; Pyrimidines; Quinazolines; Quinolones; Rituximab; Sesquiterpenes; Sesquiterpenes, Guaiane; Trastuzumab | 2005 |
Tyrphostins and other tyrosine kinase inhibitors.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Benzamides; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Graft Occlusion, Vascular; Humans; Imatinib Mesylate; Janus Kinase 2; Janus Kinase 3; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Tyrphostins | 2006 |
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Bevacizumab; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Trastuzumab | 2008 |
[Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2008 |
Chemotherapeutic agents and the skin: An update.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Hair Diseases; Humans; Imatinib Mesylate; Indoles; Mucous Membrane; Nail Diseases; Niacinamide; Phenylurea Compounds; Piperazines; Platinum Compounds; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Skin; Skin Diseases; Sorafenib; Sunitinib; Taxoids | 2008 |
Commentary: Novel therapies for cancer: why dirty might be better.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microtubules; Neoplasms; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Purinergic P2 | 2008 |
Current status of clinical trials for glioblastoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Biocompatible Materials; Brain Neoplasms; Cancer Vaccines; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Decanoic Acids; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Gefitinib; Glioblastoma; Humans; Imatinib Mesylate; Immunotoxins; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Piperazines; Polyesters; Protein Kinase Inhibitors; Proteins; Pyrimidines; Quinazolines; Sirolimus; Temozolomide; TOR Serine-Threonine Kinases; Transcription Factors | 2006 |
Clinical pharmacokinetics of tyrosine kinase inhibitors.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Benzenesulfonates; Biological Availability; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Intestinal Absorption; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Tissue Distribution | 2009 |
Pharmacogenetics of small-molecule tyrosine kinase inhibitors: Optimizing the magic bullet.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Neoplasm Proteins; Pharmacogenetics; Piperazines; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines | 2010 |
[Indications and current development of new targeted therapies in pediatric oncology].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Child; Dasatinib; Erlotinib Hydrochloride; Hedgehog Proteins; Humans; Imatinib Mesylate; Indoles; Integrins; Molecular Targeted Therapy; Neoplasms; Niacinamide; Nifurtimox; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; TOR Serine-Threonine Kinases | 2011 |
Targeted drug therapies and cancer.
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Drug Delivery Systems; Erlotinib Hydrochloride; Gastrointestinal Neoplasms; Gefitinib; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Efficacy of epidermal growth factor receptor targeting in advanced chordoma: case report and literature review.
Topics: Aged; Antineoplastic Agents; Benzamides; Bone Neoplasms; Chordoma; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Male; Molecular Targeted Therapy; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Treatment Outcome | 2011 |
Pulmonary toxicities of tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Benzamides; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Humans; Imatinib Mesylate; Lung Diseases, Interstitial; Neoplasms; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines | 2011 |
The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Cetuximab; Crizotinib; Erlotinib Hydrochloride; Eye Diseases; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Neoplasms; Phosphorylcholine; Piperazines; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Trastuzumab | 2013 |
Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs.
Topics: Antineoplastic Agents; Benzamides; Benzylisoquinolines; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Imidazoles; Lapatinib; Multidrug Resistance-Associated Proteins; Piperazines; Purines; Pyrimidines; Quinazolines; Sildenafil Citrate; Sulfonamides; Sulfones; Taxoids; Triazines; Vardenafil Dihydrochloride | 2014 |
[Clinical pharmacokinetics of small molecule tyrosine kinase inhibitors].
Topics: Antineoplastic Agents; Crown Ethers; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Glucuronosyltransferase; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2013 |
Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials as Topic; Docetaxel; Erlotinib Hydrochloride; Everolimus; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Sirolimus; Taxoids; TOR Serine-Threonine Kinases | 2015 |
[Tyrosine kinase inhibitors and pregnancy: A risk to the fetus?].
Topics: Abnormalities, Drug-Induced; Adult; Antineoplastic Agents; Dasatinib; Erlotinib Hydrochloride; Female; Fetus; Gefitinib; Humans; Imatinib Mesylate; Lapatinib; Maternal Age; Placenta; Pregnancy; Pregnancy Complications, Neoplastic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Risk | 2016 |
1 trial(s) available for erlotinib hydrochloride and imatinib mesylate
| Article | Year |
|---|---|
Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bevacizumab; Carcinoma, Renal Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Imatinib Mesylate; Kidney Neoplasms; Male; Middle Aged; Piperazines; Pyrimidines; Quinazolines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor | 2007 |
34 other study(ies) available for erlotinib hydrochloride and imatinib mesylate
| Article | Year |
|---|---|
Cancer drugs. Smart weapons prove tough to design.
Topics: Advisory Committees; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Approval; Drug Industry; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Neoplasms; Patient Selection; Piperazines; Pyrimidines; Quinazolines; United States; United States Food and Drug Administration | 2002 |
Research unveils the 'who' and 'why' of gefitinib.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Mutation; Piperazines; Pyrimidines; Quinazolines; Trastuzumab | 2004 |
[Current status and prospect of neoplasm targeted therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Drug Delivery Systems; Drug Design; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Immunologic Factors; Neoplasms; Palliative Care; Piperazines; Pyrimidines; Quinazolines; Signal Transduction | 2005 |
[Advances in the molecular target therapy in lung cancer].
Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Piperazines; Pyrimidines; Quinazolines | 2005 |
Structural analysis of protein kinase A mutants with Rho-kinase inhibitor specificity.
Topics: Animals; Benzamides; Cattle; Cyclic AMP-Dependent Protein Kinases; Erlotinib Hydrochloride; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Models, Molecular; Mutagenesis, Site-Directed; Piperazines; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; rho-Associated Kinases; Structure-Activity Relationship; Substrate Specificity | 2006 |
Pharmacy benefit spending on oral chemotherapy drugs.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States | 2006 |
New insights into oncogene addiction found.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Benzamides; Cyclin D1; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, bcl-1; Humans; Imatinib Mesylate; Mutation; Neoplasms; Oncogenes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Signal Transduction; Trastuzumab | 2007 |
Lung cancer: not just for smokers. People who never smoked may have a different form of the disease that responds better to a new generation of targeted medications.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Lung Neoplasms; Piperazines; Pyrimidines; Quinazolines; Tobacco Smoke Pollution | 2007 |
Outpacing cancer.
Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Neoplasms; Mutation; Piperazines; Pyrimidines; Quinazolines | 2009 |
Simultaneous quantification of erlotinib, gefitinib, and imatinib in human plasma by liquid chromatography tandem mass spectrometry.
Topics: Analytic Sample Preparation Methods; Benzamides; Calibration; Chromatography, High Pressure Liquid; Drug Monitoring; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Microchemistry; Piperazines; Pyrimidines; Quinazolines; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2009 |
Tyrosine kinase inhibitor-induced macrocytosis.
Topics: Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Neoplasm Staging; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2009 |
Combining an EGFR directed tyrosine kinase inhibitor with autophagy-inducing drugs: a beneficial strategy to combat non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Lung Neoplasms; Membrane Potential, Mitochondrial; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sirolimus; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2011 |
Direct, metal-free amination of heterocyclic amides/ureas with NH-heterocycles and N-substituted anilines in POCl3.
Topics: Amides; Amination; Aniline Compounds; Anticholesteremic Agents; Azabicyclo Compounds; Benzamides; Catalysis; Chemistry, Pharmaceutical; Erlotinib Hydrochloride; Eszopiclone; Fluorobenzenes; Heterocyclic Compounds; Humans; Hydrogen-Ion Concentration; Hypnotics and Sedatives; Hypoglycemic Agents; Imatinib Mesylate; Molecular Structure; Phosphorus Compounds; Piperazines; Prescription Drugs; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Rosiglitazone; Rosuvastatin Calcium; Sulfonamides; Thiazolidinediones; Urea | 2011 |
Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Brain Neoplasms; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression; Glioma; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; PTEN Phosphohydrolase; Pyrimidines; Quinazolines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Survival Rate; Tumor Cells, Cultured; Young Adult | 2012 |
Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Benzimidazoles; Cell Line; Cetuximab; Chromones; Dose-Response Relationship, Drug; Drug Resistance, Multiple; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Morpholines; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Signal Transduction; Tyrphostins | 2012 |
Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Chromatography, Liquid; Dasatinib; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Reproducibility of Results; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2013 |
Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.
Topics: Aged; Antineoplastic Agents; Benzamides; Body Weight; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Monitoring; Erlotinib Hydrochloride; Female; Gastric Acid; Half-Life; Histamine H2 Antagonists; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasms; Outpatients; Piperazines; Protein Kinase Inhibitors; Proton Pump Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Tandem Mass Spectrometry | 2014 |
New chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugs.
Topics: Animals; Axitinib; Benzamides; Erlotinib Hydrochloride; Female; HeLa Cells; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lapatinib; Mice; Morpholines; Piperazines; Protein Kinase Inhibitors; Purines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Trypanosomiasis, African | 2014 |
Autophagy facilitates the EGFR-TKI acquired resistance of non-small-cell lung cancer cells.
Topics: Antineoplastic Agents; Autophagy; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines | 2014 |
Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment.
Topics: Administration, Inhalation; Benzamides; Erlotinib Hydrochloride; Gefitinib; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines | 2014 |
Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST).
Topics: Afatinib; Aged; Aged, 80 and over; Axl Receptor Tyrosine Kinase; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunoblotting; Immunohistochemistry; Male; Middle Aged; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; Thiourea | 2015 |
Variation in transplacental transfer of tyrosine kinase inhibitors in the human perfused cotyledon model.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Fetus; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Maternal-Fetal Exchange; Mutation; Perfusion; Placenta; Pregnancy; Protein Kinase Inhibitors; Quinazolines; Tissue Distribution | 2015 |
A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Erlotinib Hydrochloride; Female; Follow-Up Studies; Hospitals, University; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome; Young Adult | 2015 |
Infectious disease. Combating emerging viral threats.
Topics: Adenine; Adenosine; Antiviral Agents; Benzamides; Chloroquine; Communicable Diseases, Emerging; Cyclosporins; Cytosine; Dengue; Drug Approval; Drug Design; Erlotinib Hydrochloride; Hemorrhagic Fever, Ebola; Humans; Imatinib Mesylate; Indoles; Organophosphonates; Piperazines; Purine Nucleosides; Pyrimidines; Pyrroles; Pyrrolidines; Quinazolines; Sunitinib; Viruses | 2015 |
Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment.
Topics: Antineoplastic Agents; Commerce; Drug Industry; Erlotinib Hydrochloride; Global Health; Humans; Imatinib Mesylate; Lapatinib; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Sorafenib | 2016 |
A Thermodynamic-Based Interpretation of Protein Expression Heterogeneity in Different Glioblastoma Multiforme Tumors Identifies Tumor-Specific Unbalanced Processes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Computational Biology; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Genes, Reporter; Genetic Heterogeneity; Glioblastoma; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Neoplasm Proteins; Phosphoproteins; Signal Transduction; Thermodynamics | 2016 |
Efficacy of erlotinib and imatinib in a patient with a rectal gastrointestinal stromal tumor and synchronous pulmonary adenocarcinoma: A case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Erlotinib Hydrochloride; Female; Gastrointestinal Stromal Tumors; Genes, erbB-1; Humans; Imatinib Mesylate; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasms, Multiple Primary; Proto-Oncogene Proteins c-kit; Rectal Neoplasms | 2016 |
Stability of extemporaneous erlotinib, lapatinib, and imatinib oral suspensions.
Topics: Administration, Oral; Chemistry, Pharmaceutical; Dosage Forms; Drug Stability; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Lapatinib; Quinazolines; Suspensions | 2016 |
Ductular reaction correlates with fibrogenesis but does not contribute to liver regeneration in experimental fibrosis models.
Topics: Animals; Carbon Tetrachloride; Cell Proliferation; Disease Models, Animal; Erlotinib Hydrochloride; Fibrosis; Imatinib Mesylate; Keratin-19; Liver; Liver Cirrhosis; Liver Regeneration; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microscopy, Confocal; Protein Kinase Inhibitors; Thioacetamide; Transforming Growth Factor beta | 2017 |
Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Chordoma; Erlotinib Hydrochloride; Female; France; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Skull Base Neoplasms; Sorafenib; Sunitinib; Treatment Outcome; Young Adult | 2017 |
Impact of pharmacy channel on adherence to oral oncolytics.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Erlotinib Hydrochloride; Female; Humans; Imatinib Mesylate; Male; Medicare; Medication Adherence; Middle Aged; Pharmaceutical Services; Pharmacies; Retrospective Studies; United States | 2017 |
[Therapeutic drug monitoring - 4th edition of the congress of pharmacology of anticancer drugs].
Topics: Antineoplastic Agents; Bayes Theorem; Bevacizumab; Colorectal Neoplasms; Drug Monitoring; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Liver; Neoplasms; Phenylurea Compounds; Pyridines | 2017 |
Tyrosine Kinase Inhibitors Imatinib and Erlotinib Increase Apoptosis of Antimitotic Drug-resistant KBV20C Cells Without Inhibiting P-gp.
Topics: Antimitotic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lapatinib; Protein Kinase Inhibitors; Vincristine | 2019 |
The development of electrochemical DNA biosensor based on poly-l-methionine and bimetallic AuPt nanoparticles coating: Picomolar detection of Imatinib and Erlotinib.
Topics: Biosensing Techniques; Carbon; DNA; Electrochemical Techniques; Electrodes; Erlotinib Hydrochloride; Gold; Humans; Imatinib Mesylate; Metal Nanoparticles; Platinum | 2023 |